- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03489096
Cryoballoon Targeting Atrial Fibrosis in Atrial Fibrillation (CANARI-AF)
CryobAllooN Targeting Atrial fibRosIs in Atrial Fibrillation
Pulmonary vein isolation (PVI) using cryoballoon ablation is a well-established procedure for the treatment of atrial fibrillation (AF). However, the use of cryoballoon ablation in recent clinical trials have been limited to PVI. As such, patients with paroxysmal AF have been the main recipients of this procedure. In patients with persistent AF, or patients with paroxysmal AF and significant AF substrate other than the pulmonary veins, the utility of cryoballoon ablation is less straightforward. In such patients, the choices are to either use cryoballoon ablation in a PVI-only approach or alternatively, use cryoballoon ablation for PVI followed by the use of radiofrequency ablation for additional ablation and/or substrate modification.
Substrate modification by targeting left atrial fibrosis detected on delayed enhancement magnetic resonance imaging (DE-MRI) is an increasingly popular approach with growing data showing its utility to decrease the risk of recurrence. The ability to use cryoballoon ablation for fibrosis based ablation in addition to PVI will therefore provide a significant advantage.
This study will evaluate feasibility and the outcome of targeted ablation of left atrial fibrosis detected on DE-MRI in addition to pulmonary vein isolation using the Arctic Front Advance Cryoballoon Catheter.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center open-label pilot study to be performed at the University of Utah Hospital. Patients that are referred for first time ablation of paroxysmal or persistent atrial fibrillation (AF) will be considered to be enrolled in the study. An electrocardiogram (ECG) will be performed at the time of the first clinic visit with the documentation of the rhythm. All patients will be started on an oral anticoagulation (either a novel anticoagulation agent or warfarin with a targeted international normalized ratio (INR) of 2-3). All patients will have a basic metabolic panel, complete blood count, prothrombin time/INR, thyroid-stimulating hormone, and a chest x-ray at the time of the first clinic visit. Women of childbearing potential will have a β-human chorionic gonadotropin test to rule out pregnancy. Within a month prior to the planned ablation, all patients will undergo a DE-MRI to assess pulmonary vein anatomy, fibrosis burden and distribution, and left ventricular function.
All patients will undergo a transesophageal echocardiogram immediately prior to the ablation procedure to rule out thrombus within the left atrial appendage. If thrombus is detected, the procedure will be postponed. AF ablation procedure will consist of pulmonary vein isolation using the Medtronic Arctic Front Advance Cryoballoon Catheter. Following PVI, additional lesions will be placed targeting areas of fibrosis by further manipulation of the catheter from its position within pulmonary vein.
Following ablation, all patients will be observed for 24 hours to assess immediate post procedural complications. All patients will be continued on anticoagulation for at least two months. Patients may be continued on oral anticoagulation beyond two months post-ablation if they are determined to have a high stroke risk profile.
A DE-MRI will be performed on all patients within 24 hours of ablation to assess esophageal thermal injury. Patients with severe esophageal enhancement will have a repeat DE-MRI within 24 hours. Patients with moderate enhancement will have a repeat DE-MRI within 1 week. All patients with persistent esophageal enhancement on repeat DE-MRI will be referred for esophagogastroduodenoscopy. All patients will be placed on a proton pump inhibitor for 1 month.
All patients will be discharged with a 60-day event monitor. Continuation of antiarrhythmic medications will be at the discretion of the performing physician. Following the procedure, a 90-day blanking period will start. Following the blanking period, patients will be monitored for one year for recurrence of AF. Recurrence of AF is defined as a detectable episode of AF, atrial flutter, or atrial tachycardia lasting at least 30 seconds. AF recurrence will be assessed by 30-day event monitors at 3, 6, and 12-months following the blanking period. A chest x-ray will be performed in all patients at the time of their first follow up visit.
All patients will undergo a DE-MRI at 3 months at the time which ablation scar size and burden, progression of left atrial fibrosis as well as presence of pulmonary vein stenosis will be assessed.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Referred for cryoballoon ablation of paroxysmal or persistent atrial fibrillation
- 18 years of age or older
- Ability to give informed consent in accordance with University of Utah IRB guidelines
Exclusion Criteria:
- Previous ablation for atrial fibrillation or atypical atrial flutter
- Contraindication to MRI contrast agent
- Unquantifiable fibrosis or moderate to severe left-atrial fibrosis (≥ 20%)
- Contraindication for chronic anticoagulation therapy
- Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular disease within the last 2 months
- Implanted cardiac device
- Presence of left atrial thrombus
- Contraindications to cryoballoon ablation including history of cryoglobulinemia, active systemic infection, and presence of one or more pulmonary vein stents
- New York Heart Association (NYHA) class IV heart failure
- Women who are currently pregnant or breast feeding or using unreliable contraceptive measures if premenopausal
- Enrollment in another investigational trial
- Untreated hyperthyroidism or hypothyroidism
- Life expectancy < 12 months due to a terminal disease
- Presence of phrenic nerve injury at baseline elicited by hemidiaphragmatic paralysis on pre-ablation chest x-ray
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cryoballoon Ablation
Cryoballoon Ablation: PVI + substrate modification.
Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation.
Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
|
Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence of Atrial Fibrillation
Time Frame: 12 Months
|
Recurrence of atrial fibrillation will be defined by detection of an episode of atrial fibrillation, atrial flutter or atrial tachycardia lasting for more than 30 seconds during any of the study follow-up periods up to one year post-ablation.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence of Atrial Fibrillation Stratified by Atrial Fibrillation Type
Time Frame: 12 Months
|
Recurrence of atrial fibrillation type will be compared to historical data of ablations targeting only pulmonary vein isolation
|
12 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nassir F Marrouche, M.D., University of Utah
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB_00109729
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Cryoballoon Ablation: PVI + substrate modification
-
AZ Sint-Jan AVActive, not recruiting
-
Ottawa Heart Institute Research CorporationUniversity of British Columbia; McGill UniversityNot yet recruitingAtrial Fibrillation | Radiofrequency Catheter Ablation | Catheter AblationCanada
-
RenJi HospitalBiosense Webster, Inc.Unknown
-
University of Texas Southwestern Medical CenterMedtronicCompletedAtrial FibrillationUnited States
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Ventricular Tachycardia | Left Ventricular DysfunctionGermany, Switzerland, Czechia, Denmark
-
Insel Gruppe AG, University Hospital BernUniversity of BernActive, not recruitingParoxysmal Atrial FibrillationSwitzerland
-
Asklepios proresearchEvangelisches Krankenhaus Düsseldorf; Asklepios Klinik St. GeorgRecruiting
-
Centro Medico TeknonCompleted
-
Insel Gruppe AG, University Hospital BernUniversity Hospital, Basel, SwitzerlandActive, not recruitingParoxysmal Atrial FibrillationSwitzerland
-
Liverpool Heart and Chest Hospital NHS Foundation...Medtronic International Trading SarlCompletedAtrial Flutter TypicalUnited Kingdom, Switzerland